Oak Therapeutics in line for SBIR award

We are proud to report that we are in the final stages of negotiating an SBIR award with the National Institute for Allergens and Infectious Diseases (NIAID). The award will allow us to develop an oral dissolvable strip for Isoniazid, a pharmaceutical used in the treatment of tuberculosis. We will soon report more details.


Featured Posts
Recent Posts
Archive